214 related articles for article (PubMed ID: 21762082)
1. Bortezomib targets the caspase-like proteasome activity in cervical cancer cells, triggering apoptosis that can be enhanced by nelfinavir.
Bruning A; Vogel M; Mylonas I; Friese K; Burges A
Curr Cancer Drug Targets; 2011 Sep; 11(7):799-809. PubMed ID: 21762082
[TBL] [Abstract][Full Text] [Related]
2. The human immunodeficiency virus-1 protease inhibitor nelfinavir impairs proteasome activity and inhibits the proliferation of multiple myeloma cells in vitro and in vivo.
Bono C; Karlin L; Harel S; Mouly E; Labaume S; Galicier L; Apcher S; Sauvageon H; Fermand JP; Bories JC; Arnulf B
Haematologica; 2012 Jul; 97(7):1101-9. PubMed ID: 22271897
[TBL] [Abstract][Full Text] [Related]
3. The TRAIL apoptotic pathway mediates proteasome inhibitor induced apoptosis in primary chronic lymphocytic leukemia cells.
Kabore AF; Sun J; Hu X; McCrea K; Johnston JB; Gibson SB
Apoptosis; 2006 Jul; 11(7):1175-93. PubMed ID: 16699949
[TBL] [Abstract][Full Text] [Related]
4. Nelfinavir and bortezomib inhibit mTOR activity via ATF4-mediated sestrin-2 regulation.
Brüning A; Rahmeh M; Friese K
Mol Oncol; 2013 Dec; 7(6):1012-8. PubMed ID: 23916134
[TBL] [Abstract][Full Text] [Related]
5. Preventing the autophagic survival response by inhibition of calpain enhances the cytotoxic activity of bortezomib in vitro and in vivo.
Escalante AM; McGrath RT; Karolak MR; Dorr RT; Lynch RM; Landowski TH
Cancer Chemother Pharmacol; 2013 Jun; 71(6):1567-76. PubMed ID: 23572175
[TBL] [Abstract][Full Text] [Related]
6. TRAIL therapy in non-small cell lung cancer cells: sensitization to death receptor-mediated apoptosis by proteasome inhibitor bortezomib.
Voortman J; Resende TP; Abou El Hassan MA; Giaccone G; Kruyt FA
Mol Cancer Ther; 2007 Jul; 6(7):2103-12. PubMed ID: 17620439
[TBL] [Abstract][Full Text] [Related]
7. Nelfinavir, an HIV protease inhibitor, induces apoptosis and cell cycle arrest in human cervical cancer cells via the ROS-dependent mitochondrial pathway.
Xiang T; Du L; Pham P; Zhu B; Jiang S
Cancer Lett; 2015 Aug; 364(1):79-88. PubMed ID: 25937300
[TBL] [Abstract][Full Text] [Related]
8. Sequential effects of the proteasome inhibitor bortezomib and chemotherapeutic agents in uterine cervical cancer cell lines.
Miyamoto Y; Nakagawa S; Wada-Hiraike O; Seiki T; Tanikawa M; Hiraike H; Sone K; Nagasaka K; Oda K; Kawana K; Nakagawa K; Fujii T; Yano T; Kozuma S; Taketani Y
Oncol Rep; 2013 Jan; 29(1):51-7. PubMed ID: 23064281
[TBL] [Abstract][Full Text] [Related]
9. Proteasome inhibitors sensitize ovarian cancer cells to TRAIL induced apoptosis.
Saulle E; Petronelli A; Pasquini L; Petrucci E; Mariani G; Biffoni M; Ferretti G; Scambia G; Benedetti-Panici P; Cognetti F; Humphreys R; Peschle C; Testa U
Apoptosis; 2007 Apr; 12(4):635-55. PubMed ID: 17252198
[TBL] [Abstract][Full Text] [Related]
10. p70S6 kinase is a target of the novel proteasome inhibitor 3,3'-diamino-4'-methoxyflavone during apoptosis in human myeloid tumor cells.
Piedfer M; Bouchet S; Tang R; Billard C; Dauzonne D; Bauvois B
Biochim Biophys Acta; 2013 Jun; 1833(6):1316-28. PubMed ID: 23481040
[TBL] [Abstract][Full Text] [Related]
11. Cooperative cytotoxicity of proteasome inhibitors and tumor necrosis factor-related apoptosis-inducing ligand in chemoresistant Bcl-2-overexpressing cells.
Nencioni A; Wille L; Dal Bello G; Boy D; Cirmena G; Wesselborg S; Belka C; Brossart P; Patrone F; Ballestrero A
Clin Cancer Res; 2005 Jun; 11(11):4259-65. PubMed ID: 15930365
[TBL] [Abstract][Full Text] [Related]
12. Mapatumumab and lexatumumab induce apoptosis in TRAIL-R1 and TRAIL-R2 antibody-resistant NSCLC cell lines when treated in combination with bortezomib.
Luster TA; Carrell JA; McCormick K; Sun D; Humphreys R
Mol Cancer Ther; 2009 Feb; 8(2):292-302. PubMed ID: 19174554
[TBL] [Abstract][Full Text] [Related]
13. Cytotoxic synergy between the multikinase inhibitor sorafenib and the proteasome inhibitor bortezomib in vitro: induction of apoptosis through Akt and c-Jun NH2-terminal kinase pathways.
Yu C; Friday BB; Lai JP; Yang L; Sarkaria J; Kay NE; Carter CA; Roberts LR; Kaufmann SH; Adjei AA
Mol Cancer Ther; 2006 Sep; 5(9):2378-87. PubMed ID: 16985072
[TBL] [Abstract][Full Text] [Related]
14. PCI-24781 induces caspase and reactive oxygen species-dependent apoptosis through NF-kappaB mechanisms and is synergistic with bortezomib in lymphoma cells.
Bhalla S; Balasubramanian S; David K; Sirisawad M; Buggy J; Mauro L; Prachand S; Miller R; Gordon LI; Evens AM
Clin Cancer Res; 2009 May; 15(10):3354-65. PubMed ID: 19417023
[TBL] [Abstract][Full Text] [Related]
15. Proteasome inhibitors synergize with tumor necrosis factor-related apoptosis-induced ligand to induce anaplastic thyroid carcinoma cell death.
Conticello C; Adamo L; Giuffrida R; Vicari L; Zeuner A; Eramo A; Anastasi G; Memeo L; Giuffrida D; Iannolo G; Gulisano M; De Maria R
J Clin Endocrinol Metab; 2007 May; 92(5):1938-42. PubMed ID: 17327374
[TBL] [Abstract][Full Text] [Related]
16. Proteasome inhibitors sensitize colon carcinoma cells to TRAIL-induced apoptosis via enhanced release of Smac/DIABLO from the mitochondria.
Nagy K; Székely-Szüts K; Izeradjene K; Douglas L; Tillman M; Barti-Juhász H; Dominici M; Spano C; Luca Cervo G; Conte P; Houghton JA; Mihalik R; Kopper L; Peták I
Pathol Oncol Res; 2006; 12(3):133-42. PubMed ID: 16998592
[TBL] [Abstract][Full Text] [Related]
17. Bortezomib abolishes tumor necrosis factor-related apoptosis-inducing ligand resistance via a p21-dependent mechanism in human bladder and prostate cancer cells.
Lashinger LM; Zhu K; Williams SA; Shrader M; Dinney CP; McConkey DJ
Cancer Res; 2005 Jun; 65(11):4902-8. PubMed ID: 15930312
[TBL] [Abstract][Full Text] [Related]
18. TNF potentiates anticancer activity of bortezomib (Velcade) through reduced expression of proteasome subunits and dysregulation of unfolded protein response.
Nowis D; McConnell EJ; Dierlam L; Palamarchuk A; Lass A; Wójcik C
Int J Cancer; 2007 Jul; 121(2):431-41. PubMed ID: 17373661
[TBL] [Abstract][Full Text] [Related]
19. Ritonavir, nelfinavir, saquinavir and lopinavir induce proteotoxic stress in acute myeloid leukemia cells and sensitize them for proteasome inhibitor treatment at low micromolar drug concentrations.
Kraus M; Müller-Ide H; Rückrich T; Bader J; Overkleeft H; Driessen C
Leuk Res; 2014 Mar; 38(3):383-92. PubMed ID: 24418752
[TBL] [Abstract][Full Text] [Related]
20. Effects of the proteasome inhibitor, bortezomib, on apoptosis in isolated lymphocytes obtained from patients with chronic lymphocytic leukemia.
Pahler JC; Ruiz S; Niemer I; Calvert LR; Andreeff M; Keating M; Faderl S; McConkey DJ
Clin Cancer Res; 2003 Oct; 9(12):4570-7. PubMed ID: 14555532
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
